Breaking News Instant updates and real-time market news.

KITE

Kite Pharma

$51.99

0.75 (1.46%)

, RF

Regions Financial

09:41
01/10/17
01/10
09:41
01/10/17
09:41

Unusually active option classes on open January 10th

Unusual total active option classes on open include: Kite Pharma (KITE), Regions Financial (RF), Express (EXPR), Sprint (S), Valeant (VRX), iShares Nasdaq Biotechnology Index Fund (IBB), Best Buy (BBY), Chipotle (CMG), Fitbit (FIT), and AT&T (T).

KITE

Kite Pharma

$51.99

0.75 (1.46%)

RF

Regions Financial

EXPR

Express

S

Sprint

VRX

Valeant

IBB

iShares Nasdaq Biotechnology Index

$284.28

4.02 (1.43%)

BBY

Best Buy

CMG

Chipotle

FIT

Fitbit

T

AT&T

  • 10

    Jan

  • 10

    Jan

  • 11

    Jan

  • 12

    Jan

  • 20

    Jan

  • 25

    Jan

  • 02

    Feb

  • 16

    Feb

  • 28

    Feb

KITE Kite Pharma
$51.99

0.75 (1.46%)

12/05/16
MAXM
12/05/16
NO CHANGE
Target $77
MAXM
Buy
Kite Pharma BLA submission a milestone for entire CAR-T space, says Maxim
Maxim analyst Jason McCarthy noted that Kite Pharma's rolling BLA submission for KTE-C19 for the treatment of relapsed/refractory non-Hodgkin lymphoma is the first BLA filed for a CAR-T therapy, calling the event "a milestone not just for Kite but for the entire CAR-T space." In a survey of 100 doctors, over two-thirds said they believe CAR-T could change how they treat lymphoma and 86% were impressed with the ZUMA-1 data, noted McCarthy, who added that Kite has also received positive feedback from payers. He keeps a Buy rating and $77 price target on Kite shares.
12/01/16
LEER
12/01/16
NO CHANGE
LEER
Outperform
bluebird bio data looks 'impressive,' says Leerink
Leerink analyst Michael Schmidt notes that bluebird bio (BLUE) announced first clinical data from its ongoing Phase I study of anti-BCMA CAR-T product candidate "bb2121" in relapsed/refractory multiple myeloma, and says it looks 'impressive." While he cautions that the data is still "somewhat immature," the early results justify the high level of excitement around the potential of anti-BCMA CAR-T therapy in relapsed/ refractory myeloma, as several other companies including Juno Therapeutics (JUNO), Kite Pharma (KITE) and Novartis (NVS) have stated plans to also develop anti-BCMA-CART product candidates. Schmidt reiterates an Outperform rating on bluebird bio's shares.
01/04/17
ROTH
01/04/17
INITIATION
Target $68
ROTH
Buy
Kite Pharma initiated with a Buy at Roth Capital
Roth Capital analyst Mark Breidenbach started Kite Pharma with a Buy rating and $68 price target as he believes clinical data supports accelerated approval of the company's lead program, KTE-C19, in diffuse large B-cell lymphoma.
11/29/16
ADAM
11/29/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma benefits from program delays at Juno, says Canaccord
Canaccord analyst John Newman believes Kite Pharma (KITE) will benefit from the program delays at Juno Therapeutics (JUNO). Two deaths in Juno's Phase 2 ROCKET trial may prompt safety questions for its drug to be used in refractory NHL, which raises the upside potential for Kite when its presents its data at the ASH conference. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
RF Regions Financial

11/28/16
11/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AbbVie (ABBV) downgraded to Neutral from Buy at Citi. 2. Citi (C), Wells Fargo (WFC), and Regions Financial (RF) were downgraded to Hold from Buy at Jefferies with analyst Ken Usdin citing valuation. 3. Hilton (HLT) and Marriott (MAR) were downgraded to Hold from Buy at Evercore ISI. 4. H&R Block (HRB) downgraded to Sell from Neutral at BTIG with analyst Mark Palmer noting that President-elect Trump has said he wants to put H&R Block out of business by simplifying the tax code. 5. Tupperware Brands (TUP) downgraded to Sell from Neutral at B. Riley with analyst Linda Bolton Weiser saying the stock has not moved lower to reflect post-election currency devaluations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/28/16
JEFF
11/28/16
DOWNGRADE
Target $14
JEFF
Hold
Regions Financial downgraded to Hold from Buy at Jefferies
Jefferies analyst Ken Usdin downgraded Regions Financial to Hold citing valuation with the stock up 21% since November 8. The analyst raised his price target for the shares to $14 from $11.50.
12/01/16
SUSQ
12/01/16
DOWNGRADE
Target $12
SUSQ
Neutral
Regions Financial downgraded to Neutral due to valuation at Susquehanna
As previously reported, Susquehanna downgraded Regions Financial to Neutral from Positive and raised its price target to $15 from $12. Analyst Jack Micenko changed his view due to valuation and said most of the optimism around economic growth, higher rates, reduced regulation, and lower taxes is reflected in shares.
12/01/16
SUSQ
12/01/16
DOWNGRADE
SUSQ
Neutral
Regions Financial downgraded to Neutral from Positive at Susquehanna
EXPR Express

08/24/16
WEDB
08/24/16
DOWNGRADE
WEDB
Neutral
Express downgraded to Neutral from Outperform at Wedbush
08/24/16
PIPR
08/24/16
DOWNGRADE
PIPR
Neutral
Express downgraded to Neutral from Overweight at Piper Jaffray
08/25/16
UBSW
08/25/16
DOWNGRADE
Target $10
UBSW
Sell
Express downgraded to Sell from Neutral at UBS
UBS analyst Michael Binetti downgraded Express to Sell and lowered its price target to $10 from $16. The analyst sees downside earnings risk despite the lowered guidance given deteriorating traffic, August traffic trends that he believes are running at the low end, product issues, and potential margin pressure as the company steps up direct mail marketing in 2H 2016.
08/24/16
KING
08/24/16
DOWNGRADE
KING
Neutral
Express downgraded to Neutral from Buy at CL King
S Sprint

12/07/16
OPCO
12/07/16
NO CHANGE
Target $70
OPCO
Outperform
T-Mobile price target raised to $70 from $55 at Oppenheimer
Oppenheimer analyst Timothy Horan raised his price target for T-Mobile (TMUS) to $70 from $55 as he views it as the best way to play the deregulatory/technology driven consolidation. The analyst notes that President-Elect Trump met with Masayoshi Son of SoftBank (SFTBF), who agreed to invest $50B in the U.S. Horan believes the meeting will likely be a precursor to a Sprint (S)/T-Mobile/Dish (DISH) merger to create a discounted quad-play service company. The analyst reiterates an Outperform rating on T-Mobile' shares, and points out that the company has improved its network and taken share from AT&T (T)/Verizon (VZ).
12/21/16
OPCO
12/21/16
NO CHANGE
OPCO
T-Mobile could be worth $80/share in potential takeover, says Oppenheimer
Oppenheimer analyst Timothy Horan continues to believe that either Comcast (CMCSA; CMCSK) or Sprint (S) is the likely merger partner for T-Mobile (TMUS), potentially prompting a bidding war. Moreover, the analyst believes it is not unreasonable for Comcast or Sprint to pay $80/share for T-Mobile, or even higher. Commenting on Microsoft's (MSFT) valuation, Horan says he examined the sum of its parts, valuing Azure, its Cloud Software, and "legacy Microsoft" to arrive at a conservative $70 valuation. Additionally, he sees a major inflection in top/bottom-line growth in 2019 as Microsoft's cloud services, specifically Azure, grow more rapidly/profitably than the Wall Street expects.
01/05/17
FBRC
01/05/17
NO CHANGE
Target $11
FBRC
Outperform
Sprint price target raised to $11 from $8 at FBR Capital
FBR Capital analyst David Dixon raised his price target for Sprint (S) to $11 saying the introduction of higher-power devices this year should drive improved subscriber and free cash flow growth. The passage of the High Power User Equipment by the 3GPP standards body should raise Sprint's spectrum-portfolio value, increasing the asset's appeal across the industry as well as the probability of a merger with T-Mobile (TMUS) under a new Republican-led Administration, Dixon tells investors in a research note. He keeps an Outperform rating on Sprint shares.
11/21/16
DBAB
11/21/16
NO CHANGE
DBAB
Buy
Deutsche says buy American Tower, Crown Castle after pullbacks
Deutsche Bank analyst Matthew Niknam recommends buying shares of American Tower (AMT) and Crown Castle (CCI) following the recent selloffs. The analyst thinks estimates have bottomed, fundamentals are "very strong" and that fears of a possible Sprint (S) and T-Mobile (TMUS) merger are overblown.
VRX Valeant

01/10/17
BMOC
01/10/17
NO CHANGE
Target $21
BMOC
Market Perform
Valeant sales of Dendreon, CeraVe a 'good start,' says BMO Capital
BMO Capital analyst Gary Nachman said Valeant's (VRX) sales of Dendreon to Sanpower Group and CeraVe, AcneFree and AMBI to L'Oreal (LRLCY) for roughly $2.1B in cash have a combined average sales multiple of 4.4x, which appears to be a "solid price" and a good start for the company as it looks to sell additional assets to address its debt. Nachman also noted that Valeant announced that its second Phase 3 study for IDP-118 was successful, though he remains cautious on the drug given that most psoriasis creams are generic at this point. The analyst keeps a Market Perform rating and $21 price target on Valeant shares, which are up nearly 13% to $17.31 in pre-market trading.
01/10/17
WELS
01/10/17
NO CHANGE
WELS
Underperform
Valeant hiked prices on over 50 products last week, says Wells Fargo
Wells Fargo analyst David Maris said last night that on January 6, Valeant Pharmaceuticals implemented 95 different price increases across more than 50 products. This shows the company continues to rely on price as a means of growth and may also signal that Valeant's prescription volumes continue to remain challenged, Maris told investors in a research note. He reminds investors that Friday's price hikes "come on top of significant price increases--some of them more than 100%--taken on products in previous years and several taken in late 2016." Maris continues to believe the "new Valeant" is the "same Valeant using the same strategy and pricing levers that have been used before." The analyst keeps an Underperform rating on the shares with a $10-$13 price target range. The stock is up 12% to $17.20 in pre-market trading following the announcement of several asset sales.
12/22/16
NEED
12/22/16
NO CHANGE
NEED
AMAG Pharmaceuticals, Corium top pharma picks for 2017 at Needham
Needham analyst Serge Belanger says that while 2016 kicked off with "the wrong kind of bang" for specialty pharma/biopharma equities, with the unraveling of the rollup strategies espoused by Valeant Pharmaceuticals (VRX) and Endo (ENDP) and the political rhetoric around drug pricing as headwinds throughout the year, the election outcome provides a more positive outlook for 2017. Nonetheless, the analyst believes the political uncertainty around drug pricing is likely to remain an ongoing but diminished concern with the new administration. Additionally, he expects some of the proposed tax changes of the new administration to be key drivers for driving M&A volumes in 2017 and beyond. Belanger believes this bodes well for companies in the classic spec pharma therapeutics areas that have historically benefited from consolidation, and said his top picks for 2017 are AMAG Pharmaceuticals (AMAG) and Corium (CORI).
01/04/17
PIPR
01/04/17
NO CHANGE
Target $11
PIPR
Underweight
Piper calls Valeant 'not investable,' cuts target to $11
Piper Jaffray analyst David Amsellem cut his price target for Valeant Pharmaceuticals to $11 from $16 and reiterates an Underweight rating on the shares. The drugmaker closed yesterday up 72c to $15.24. After taking a closer look at prescription trends across the company's U.S. business, Amsellem believes shares of Valeant are "not investable." The company faces "significant pressure" from generic competition on high-margin assets while the "picture on the whole continues to look challenging," the analyst tells investors in a research note. He believes the likelihood of "significant pressure on the shares is far higher than that of potential recovery."
IBB iShares Nasdaq Biotechnology Index
$284.28

4.02 (1.43%)

03/23/16
JEFF
03/23/16
NO CHANGE
JEFF
Jefferies believes most of the biotech downside has already occurred
The Jefferies Biotechnology team, led by Brian Abrahams, believes most of the significant downside in Biotechnology shares has already occurred with the iShares NASDAQ Biotechnology Index (IBB) down 22% year-to-date. Nonetheless, volatility in the space could persist with funds flowing out of healthcare and negative drug pricing rhetoric, the analysts tell investors in a research note. They view any weakness in the space as "excellent" long-term buying opportunities for companies with "concrete" earnings outlooks and "promising" pipelines. The analysts highlight Vertex (VRTX), BioMarin (BMRN), The Medicines Co. (MDCO), Ultragenyx (RARE) and Vanda (VNDA) as names to focus on.
BBY Best Buy

12/06/16
LOOP
12/06/16
INITIATION
Target $58
LOOP
Buy
Best Buy initiated with a Buy at Loop Capital
Loop Capital initiated Best Buy with a Buy rating and $58 price target.
11/18/16
UBSW
11/18/16
NO CHANGE
Target $47
UBSW
Neutral
Best Buy fairly valued at current levels, says UBS
UBS analyst Michael Lasser noted Best Buy continued to outperform and take market share in Q3. He said the market share gains drove solid comp growth during the quarter and believes increasing its international operating margins is a long-term opportunity for the company. Lasser feels Best Buy shares are fairly valued at current levels and reiterated his Neutral rating while raising his price target on the shares to $47 from $38.
11/18/16
WEDB
11/18/16
NO CHANGE
WEDB
Best Buy outlook remains negative, says Wedbush
After Best Buy reported stronger than expected results, Wedbush analyst Michael Pachter still expects the company's holiday sales to be hurt by weakness in TV and wearables. The analyst says the fact that the company does not plan to issue a press release on its holiday sales bodes badly for its performance. He keeps a $24.50 price target and an Underperform rating on the shares.
01/05/17
OPCO
01/05/17
NO CHANGE
OPCO
Traditional chains fighting back as Amazon remains leader, says Oppenheimer
Oppenheimer analyst Brian Nagel says that during the Holiday season his firm ordered one item from eight Hardlines/Broadlines retailers and performed an informal test to see how the shopping experience compared to Amazon (AMZN). While the analyst notes that the e-commerce giant remains the leader online, he says traditional chains are fighting back with sharper pricing and improvements to fulfillment and return capabilities. Among traditional chains, Bed Bath & Beyond (BBBY), Costco (COST), and Wal-Mart (WMT) performed best on pricing, while Best Buy (BBY) scored as the best in fulfillment, Nagel says.
CMG Chipotle

01/05/17
01/05/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. MasterCard (MA) upgraded to Top Pick from Outperform at RBC Capital with analyst Daniel Perlin saying the company will benefit from improvements in the global economy, along with accelerating revenue growth, its recent acquisition of VocaLink, inflation, and new technological innovations. 2. Etsy (ETSY) upgraded to Buy from Hold at Loop Capital with analyst Blake Harper saying the company has done something most other retailers have not - fend off competition from Amazon (AMZN). The analyst does not expect Amazon to attract a meaningful share of Etsy shops and products. He raised his price target for Etsy shares to $16 from $14. 3. Chipotle (CMG) upgraded to Neutral from Underperform at Wedbush. 4. Progressive (PGR) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Kai Pan expecting core margins to inflect in 2017 due to a moderation in new business "drag," easier commercial auto comps in the second half of 2017, and sees additional upside from a lower tax rate and rising yield. 5. Southwest (LUV) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Rajeev Lalwani citing its Domestic exposure and defensive positioning. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/05/17
WEDB
01/05/17
UPGRADE
WEDB
Neutral
Chipotle upgraded to Neutral from Underperform at Wedbush
01/06/17
DBAB
01/06/17
NO CHANGE
Target $280
DBAB
Sell
Deutsche stays cautious on Chipotle with $280 price target
In a research note titled "Recovery 'Is A Riddle, Wrapped Up In a Burrito, Inside A Foil,'" Deutsche Bank analyst Brett Levy keeps a Sell rating on Chipotle Mexican Grill with a $280 price target. The stock closed yesterday up $10.03 to $391.89. The investment story remains based on hope of a recovery as sales have failed to accelerate, Levy tells investors. Management is moving in the right direction but that does not mean Chipotle will reach its 2017 targets, he cautions.
01/06/17
UBSW
01/06/17
NO CHANGE
Target $410
UBSW
Neutral
Chipotle sales recovery remains elusive, says UBS
UBS analyst Dennis Geiger noted Chipotle implemented an enhanced food safety program and robust marketing and promotions and other traffic enhancing efforts but the sales recovery remains elusive. The analyst said without a more accelerated sales recovery, margins are likely to remain depressed. Geiger maintained his Neutral rating and $410 price target on Chipotle shares.
FIT Fitbit

12/21/16
PACS
12/21/16
NO CHANGE
PACS
Fitbit inventory continued to rise, says Pacific Crest
After conducting checks, Pacific Crest analyst Brad Erickson says that the inventory of Fitbit devices continued to rise "exiting the quarter" in the U.S. As a result, the analyst thinks that Fitbit's Q1 results could miss expectations. He keeps a Sector Weight rating on the stock.
01/10/17
CLVD
01/10/17
NO CHANGE
CLVD
Fitbit consensus estimates at risk, says Cleveland Research
Cleveland Research analyst Ben Bollin heard Fitbit device production was halted in mid-December because of accumulating inventory and disappointing sales, resulting in increased risk to consensus Q4 and Q1estimates. Further, initial 2017 demand is characterized as weak, presenting additional risk to Bollin's down 3% unit growth estimate for 2017.
12/08/16
12/08/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Fitbit (FIT) downgraded to Hold from Buy at Deutsche Bank with analyst Sherri Scribner saying growth in the wearables market is slowing while the company's recent demand has decelerated. 2. AZZ Inc. (AZZ) downgraded to Sell from Hold at Stifel with analyst Noelle Dilts saying she believes shares are extended ahead of third quarter results that could miss investor expectations. 3. CYS Investments (CYS) downgraded to Sell from Neutral at Compass Point analyst Fred Small citing increased interest rate volatility. 4. L-3 Communications (LLL) downgraded to Neutral from Buy at BofA/Merrill analyst Ronald Epstein citing valuation and a disappointing 2017 revenue outlook. 5. EMCOR downgraded to Hold from Buy at Stifel with analyst Noelle Dilts citing balanced risk/reward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/22/16
SBSH
12/22/16
NO CHANGE
Target $8
SBSH
Neutral
Fitbit price target lowered to $8 from $10 at Citi
Citi analyst Stanley Kovler lowered his price target for Fitbit to $8 saying he's not expecting any big events or product announcements at CES 2017. The analyst cut his 2017 earnings per share estimate for the company to 60c from 77c. He sees "aggressive pricing" on Fitbit's fitness trackers post Black Friday discounts to impact the company's margins in Q4 and into 2017. Kovler keeps a Neutral rating on the shares.
T AT&T

12/12/16
12/12/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. ConocoPhillips (COP) upgraded to Outperform from Market Perform at Cowen with analyst Charles Robertson II saying that the company has positioned itself for significant earnings before interest, tax, depreciation and amortization and cash flow growth despite relatively flat production in 2017. 2. Hanesbrands (HBI) upgraded to Buy from Neutral at CL King and to Buy from Neutral at DA Davidson. 3. AT&T (T) upgraded to Outperform from Neutral at Baird with analyst William Power saying he is positive on the recent media moves, and believes the Trump administration's focus on deregulation and lower tax rates can be a tailwind. 4. Web.com (WEB) upgraded to Overweight from Neutral at JPMorgan with analyst Sterling Auty citing valuation with the shares down 12% year-to-date. 5. lululemon (LULU) upgraded to Market Perform from Underperform at FBR Capital with analyst Susan Anderson saying the company's same-store-sales and gross margin performance in the third quarter were much better than expected. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/23/16
12/23/16
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst upgrades, downgrades and initiations with this list compiled by The Fly: 1. Brean Capital analyst Alan Gould downgraded Time Warner (TWX) to Hold from Buy, saying the arbitrage discount to the AT&T (T) offer has shrunk to 12%, down from the high-teens, and Time Warner shares now trade above his fundamental value estimate in the low $90's. 2. Argus downgraded Sun Life Financial (SLF) to Hold from Buy, with analyst Jacob Kilstein citing valuation and what he sees as "weakness in the core Canadian business, lower margins, the negative impact of a strengthening Canadian dollar," along with the company's suspension of share repurchases. 3. FedEx (FDX) initiated with a Buy at Aegis. The firm also initiated shipping peer UPS (UPS) with a Hold rating. 4. Video game retailer GameStop (GME) initiated with a Buy at Mizuho, which also started coverage of video game makers Zynga (ZNGA) and Glu Mobile (GLUU) with ratings of Buy and Neutral, respectively. 5. Skechers (SKX) upgraded to Buy from Neutral at Monness Crespi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/23/16
BMUR
12/23/16
DOWNGRADE
BMUR
Hold
Time Warner downgraded to Hold from Buy at Brean Capital
Brean Capital analyst Alan Gould downgraded Time Warner (TWX) to Hold saying the arbitrage discount to the AT&T (T) offer has shrunk to 12%, down from the high-teens. Time Warner shares now trade above the analyst's fundamental value of the low $90's. Gould also believes other names in the group have become more attractive, namely CBS (CBS) and 21st Century Fox (FOXA). Gould this morning also raised his price target for CBS to $75 from $65. He kept a Buy rating on the shares.
01/10/17
FBCO
01/10/17
NO CHANGE
Target $125
FBCO
Outperform
Disney deal for Netflix 'hard to justify' at current levels, says Credit Suisse
Credit Suisse analyst Omar Sheikh weighed in on the debate as to whether Disney (DIS) should bid to acquire Netflix (NFLX), concluding that the dilution to earnings, free cash flow and to returns at the current share price would be prohibitive. Additionally, the strategic pressure to acquire a distributor is moderating with industry trends improving, Sheikh tells investors. However, this debate is unlikely to go away, given the pending merger of AT&T (T) and Time Warner (TWX), the continued growth of subscription video on demand aggregators and Disney's upcoming sports rights renewals, adds Sheikh, who keeps an Outperform rating and $125 price target on Disney shares.

TODAY'S FREE FLY STORIES

NVCR

Novocure

$21.50

-0.1 (-0.46%)

18:27
09/24/17
09/24
18:27
09/24/17
18:27
Hot Stocks
Combination of Novocure Optune with Temozolomide demonstrates five-year survival »

Novocure announced today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$102.40

-0.09 (-0.09%)

, CMCSA

Comcast

$38.10

0.63 (1.68%)

17:10
09/24/17
09/24
17:10
09/24/17
17:10
Hot Stocks
Box Office Battle: 'Kingsman: The Golden Circle' easily wins weekend »

"Kingsman: The…

TWX

Time Warner

$102.40

-0.09 (-0.09%)

CMCSA

Comcast

$38.10

0.63 (1.68%)

CMCSK

Comcast

SNE

Sony

$37.50

0.04 (0.11%)

FOX

21st Century Fox

$26.43

0.1 (0.38%)

FOXA

21st Century Fox

$26.88

0.12 (0.45%)

LGF.A

Lionsgate

$31.49

0.24 (0.77%)

DIS

Disney

$98.60

-0.29 (-0.29%)

VIAB

Viacom

$27.64

0.24 (0.88%)

VIA

Viacom

$38.00

-0.2 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 29

    Sep

  • 22

    Oct

  • 26

    Oct

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

16:41
09/24/17
09/24
16:41
09/24/17
16:41
Periodicals
Amazon affiliate to buy stake in Indian retailer Shoppers Stop, Reuters says »

An affiliate of Amazon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

, GOOG

Alphabet

$928.53

-3.92 (-0.42%)

16:37
09/24/17
09/24
16:37
09/24/17
16:37
Periodicals
Internet giants on the defensive in Washington, Reuters says »

Internet giants,…

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

FB

Facebook

$170.54

-0.57 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

  • 29

    Nov

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

, UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

16:25
09/24/17
09/24
16:25
09/24/17
16:25
Periodicals
Opposition to new 'Obamacare' repeal bill grows, Reuters reports »

The new proposal by…

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

CNC

Centene

$92.22

1.48 (1.63%)

WCG

WellCare

$167.16

1.1 (0.66%)

CI

Cigna

$182.74

0.61 (0.33%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

AET

Aetna

$153.57

0.18 (0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

  • 08

    Nov

SAP

SAP

$110.27

0.64 (0.58%)

16:11
09/24/17
09/24
16:11
09/24/17
16:11
Hot Stocks
SAP announces acquisition of Gigya »

SAP has announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TATT

TAT Technologies

$10.70

0.05 (0.47%)

, BA

Boeing

$256.45

0.41 (0.16%)

16:03
09/24/17
09/24
16:03
09/24/17
16:03
Hot Stocks
TAT Technologies awarded APU MRO contract for fleet of Boeing, Airbus »

TAT Technologies (TATT),…

TATT

TAT Technologies

$10.70

0.05 (0.47%)

BA

Boeing

$256.45

0.41 (0.16%)

EADSY

Airbus

$23.06

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

GM

General Motors

$39.42

0.32 (0.82%)

11:43
09/23/17
09/23
11:43
09/23/17
11:43
Periodicals
GM to eliminate shift at Tennessee SUV plant on 'moderating' sales, WSJ says »

General Motors has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.25

0.19 (0.35%)

11:34
09/23/17
09/23
11:34
09/23/17
11:34
Periodicals
Wells Fargo hires law firm to prepare CEO for Senate appearance, Reuters says »

Wells Fargo has hired law…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 03

    Oct

  • 13

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

EADSY

Airbus

$23.06

-0.01 (-0.04%)

11:27
09/23/17
09/23
11:27
09/23/17
11:27
Periodicals
Airbus in talks to sell all or part of Premium Aerotec, Reuters says »

Airbus is said to be in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$102.11

0.56 (0.55%)

11:06
09/23/17
09/23
11:06
09/23/17
11:06
Hot Stocks
Quest Diagnostics 'disappointed' with proposed PAMA 2018 Medicare payment rates »

Quest Diagnostics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

IRBT

iRobot

$76.14

-3.8 (-4.75%)

10:58
09/23/17
09/23
10:58
09/23/17
10:58
Periodicals
iRobot suffering after onslaught of SharkNinja cheaper models, Barron's says »

In a follow up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$69.33

0.42 (0.61%)

, SNPS

Synopsys

$80.36

0.3 (0.37%)

10:47
09/23/17
09/23
10:47
09/23/17
10:47
Periodicals
Xilinx, Synopsys are 'rising stars' amid natural evolution of AI, Barron's says »

As everyday items get…

XLNX

Xilinx

$69.33

0.42 (0.61%)

SNPS

Synopsys

$80.36

0.3 (0.37%)

CDNS

Cadence Design

$38.88

0.45 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

UTX

United Technologies

$115.01

0.51 (0.45%)

, COL

Rockwell Collins

$130.48

0.09 (0.07%)

10:42
09/23/17
09/23
10:42
09/23/17
10:42
Periodicals
Major aircraft makers, suppliers face off, Barron's says »

While United Technologies…

UTX

United Technologies

$115.01

0.51 (0.45%)

COL

Rockwell Collins

$130.48

0.09 (0.07%)

BA

Boeing

$256.45

0.41 (0.16%)

EADSY

Airbus

$23.06

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

GPRO

GoPro

$10.75

-0.19 (-1.74%)

10:33
09/23/17
09/23
10:33
09/23/17
10:33
Periodicals
Key events may create 'short squeeze' in GoPro stock, Barron's says »

GoPro, a heavily shorted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$29.91

0.18 (0.61%)

, RACE

Ferrari

$113.47

-0.1 (-0.09%)

10:17
09/23/17
09/23
10:17
09/23/17
10:17
Periodicals
Honda $200,000 Acura NSX lacks Ferrari 'raw appeal,' Barron's says »

Acura, Honda's (HMC)…

HMC

Honda

$29.91

0.18 (0.61%)

RACE

Ferrari

$113.47

-0.1 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$48.16

0.19 (0.40%)

10:07
09/23/17
09/23
10:07
09/23/17
10:07
Periodicals
Oracle shares could return 20% in a year, Barron's says »

Oracle is a latecomer to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$58.96

1.14 (1.97%)

09:59
09/23/17
09/23
09:59
09/23/17
09:59
Periodicals
Six Flags may have peaked, Barron's says »

Investors have had an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

, AVXS

AveXis

$92.11

-4.03 (-4.19%)

09:51
09/23/17
09/23
09:51
09/23/17
09:51
Periodicals
Gene therapy may be nearing 'major breakthrough,' Baron's says »

Gene therapy is rapidly…

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

  • 22

    Sep

AET

Aetna

$153.57

0.18 (0.12%)

, ANTM

Anthem

$182.86

-0.64 (-0.35%)

09:25
09/23/17
09/23
09:25
09/23/17
09:25
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CNC

Centene

$92.22

1.48 (1.63%)

CI

Cigna

$182.74

0.61 (0.33%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

WCG

WellCare

$167.16

1.1 (0.66%)

AOBC

American Outdoor Brands

$15.01

-0.15 (-0.99%)

RGR

Sturm, Ruger

$51.00

-1.85 (-3.50%)

WMT

Wal-Mart

$79.53

-0.48 (-0.60%)

PEP

PepsiCo

$111.85

-0.95 (-0.84%)

TGT

Target

$58.99

0.66 (1.13%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

MSFT

Microsoft

$74.41

0.2 (0.27%)

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

TWTR

Twitter

$17.61

0.03 (0.17%)

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

FB

Facebook

$170.54

-0.57 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

  • 22

    Oct

  • 24

    Oct

  • 08

    Nov

  • 16

    Nov

  • 21

    Nov

  • 29

    Nov

  • 20

    Feb

AVA

Avista

$51.40

0.1 (0.19%)

18:47
09/22/17
09/22
18:47
09/22/17
18:47
Hot Stocks
Avista receives commission decision in Oregon natural gas rate case »

Avista's natural gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

BMWYY

BMW

$34.00

0.083 (0.24%)

18:40
09/22/17
09/22
18:40
09/22/17
18:40
Periodicals
BMW to build new 8 series in Dingolfing from 2018, Reuters reports »

BMW intends to build its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$33.37

0.67 (2.05%)

18:20
09/22/17
09/22
18:20
09/22/17
18:20
Hot Stocks
Cisco completes acquisition of Springpath »

Cisco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

BMY

Bristol-Myers

$63.36

0.03 (0.05%)

18:12
09/22/17
09/22
18:12
09/22/17
18:12
Hot Stocks
Bristol-Myers announces FDA approval of Opdivo »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

INSE

Inspired Entertainment

$13.60

0.3 (2.26%)

17:38
09/22/17
09/22
17:38
09/22/17
17:38
Hot Stocks
Inspired Entertainment COO Wilson leaving by reason of redundancy »

On September 21, Inspired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.